Skip to search formSkip to main contentSkip to account menu

sorafenib

Known as: 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide, SFN 
A drug used to treat advanced kidney cancer and a type of liver cancer that cannot be removed by surgery. It is also being studied in the treatment… 
National Institutes of Health

Related topics

Related topics

10 relations

Broader (4)

Antineoplastic AgentsNiacinamidePhenylurea CompoundsProtein Kinase Inhibitors
NCIt Antineoplastic Agent TerminologySorafenib:MCnc:Pt:Ser/Plas:Qnanalogs & derivativessorafenib 200 MG Oral Tablet [Nexavar]

Narrower (1)

Nexavar

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2018
Highly Cited
2018
SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma.
Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma… 
Review
2012
Review
2012
Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeutics
Hepatocellular carcinoma (HCC) is a common malignancy in developing countries and its incidence is on the rise in the developing… 
Highly Cited
2011
Highly Cited
2011
Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
Sorafenib, a potent multikinase inhibitor, has been recognized as the standard systemic treatment for patients with advanced… 
Highly Cited
2010
Highly Cited
2010
Depletion of Tumor-Associated Macrophages Enhances the Effect of Sorafenib in Metastatic Liver Cancer Models by Antimetastatic and Antiangiogenic Effects
Purpose: To investigate the role of macrophages in tumor progression under sorafenib treatment and to explore whether combination… 
Review
2010
Review
2010
Activity of Sorafenib against Desmoid Tumor/Deep Fibromatosis
Background: Desmoid tumors (deep fibromatoses) are clonal connective tissue malignancies that do not metastasize, but have a… 
Highly Cited
2009
Highly Cited
2009
MicroRNA-122 Inhibits Tumorigenic Properties of Hepatocellular Carcinoma Cells and Sensitizes These Cells to Sorafenib*
MicroRNAs are negative regulators of protein coding genes. The liver-specific microRNA-122 (miR-122) is frequently suppressed in… 
Highly Cited
2008
Highly Cited
2008
Phase II trial of sorafenib in advanced thyroid cancer.
PURPOSE Given the molecular pathophysiology of thyroid cancer and the spectrum of kinases inhibited by sorafenib, including Raf… 
Highly Cited
2008
Highly Cited
2008
Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma.
PURPOSE Sunitinib and sorafenib are tyrosine kinase inhibitors (TKIs) that have considerable efficacy in metastatic renal cell… 
Highly Cited
2008
Highly Cited
2008
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
PURPOSE Sorafenib is an antiangiogenic agent with activity in renal cancer. We conducted a randomized trial to investigate… 
Highly Cited
2006
Highly Cited
2006
Soluble fibrin inhibits monocyte adherence and cytotoxicity against tumor cells: implications for cancer metastasis
BackgroundSoluble fibrin (sFn) is a marker for disseminated intravascular coagulation and may have prognostic significance… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)